share_log

香雪制药(300147.SZ)：TCR-T和CAR-T都是过继免疫细胞治疗

Xiang Xue Pharmaceutical (300147.SZ): TCR-T and CAR-T are both adjuvant immune cell treatments

Gelonghui Finance ·  May 11 03:17

Gelonghui, May 11 | Xiangxue Pharmaceutical (300147.SZ) said on the interactive platform that TCR-T and CAR-T are both secondary immune cell treatments, that is, immune cells are isolated from cancer patients, genetically modified and amplified in vitro, and then transported back to the patient's body, but their mechanisms for recognizing antigens are quite different. CAR-T cells use antibody fragments that bind to specific antigens on the surface of cancer cells. TCR-T cells can recognize tumor-specific antigens from the surface of cell membranes or from within cells, and can target most tumor-specific antigens, especially those within tumor cells. Therefore, TCR-T cell therapy has a wider range of targets and has more potential to break through the strong line of defense against solid tumors. The mechanism of action of TCR-T is to introduce new genes into normal T cells, so that modified T cells can express TCR that effectively recognizes tumor cells, thereby guiding T cells to kill tumor cells. The basic treatment process is to isolate immunoactive cells from cancer patients, amplify and evaluate their function in vitro, and then return them to the patient to achieve the goal of directly killing the tumor or stimulating the body's immune response to kill tumor cells. Compared to CAR-T, TCR-T has obvious advantages: First, TCR-T can target not only cell surface antigens, but also intracellular antigens. For this reason, TCR-T technology is more widely used than CAR-T, and TCR-T technology has obvious advantages, especially in the field of solid tumors. Second, compared to CAR-T, TCR-T penetrates more easily into solid tumors. Finally, TCR-T introduces a completely humanized structure that is less likely to cause immune rejection by the body, and the probability of antibody production is low, so safety risks are also greatly reduced.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment